The goal of this retrospective study is to assess efficacy and safety of emapalumab prescribed for the treatment in children with refractory from of pHLH.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Dynamics of severity clinical and laboratory activity using scale H-score.
Timeframe: at the day the first dose of study treatment was administered, further at days 14, 28 and at the end of treatment, an average 45 days